The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health ...

Number 5: FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...

HADLIMA is a tumor necrosis factor (TNF) blocker indicated for appropriate patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial ...

INCHEON, Korea & JERSEY CITY, N.J. - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) have announced the U.S. Food and Drug Administration’s (FDA) approval of HADLIMA™ (adalimumab-bwwd) as an ...

Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

INCHEON, Korea & JERSEY CITY, N.J. - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) have announced the U.S. Food and Drug Administration’s (FDA) approval of HADLIMA™ (adalimumab-bwwd ...